BMCM
ABBV icon

Bryn Mawr Capital Management’s AbbVie ABBV Stock Holding History

Bryn Mawr Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.23M Buy
8,879
+326
+4% +$70.1K 0.1% 150
2026
Q1 		$1.86M Sell
8,553
-564
-6% -$125K 0.09% 157
2025
Q4 		$2.08M Buy
9,117
+1,031
+13% +$235K 0.1% 144
2025
Q3 		$1.87M Buy
8,086
+379
+5% +$77.2K 0.09% 157
2025
Q2 		$1.43M Sell
7,707
-176
-2% -$32.7K 0.08% 174
2025
Q1 		$1.65M Buy
7,883
+729
+10% +$142K 0.1% 159
2024
Q4 		$1.27M Buy
7,154
+306
+4% +$56.3K 0.07% 190
2024
Q3 		$1.35M Buy
6,848
+436
+7% +$81.4K 0.07% 189
2024
Q2 		$1.1M Sell
6,412
-8,651
-57% -$1.43M 0.06% 205
2024
Q1 		$1.16M Buy
15,063
+8,673
+136% +$1.49M 0.07% 209
2023
Q4 		$990K Sell
6,390
-248
-4% -$36.2K 0.06% 214
2023
Q3 		$989K Buy
6,638
+4,684
+240% +$688K 0.06% 209
2023
Q2 		$263K Sell
1,954
-410
-17% -$60.1K 0.02% 256
2023
Q1 		$377K Sell
2,364
-1,822
-44% -$279K 0.04% 217
2022
Q4 		$676K Buy
4,186
+1,222
+41% +$187K 0.07% 185
2022
Q3 		$398K Buy
2,964
+119
+4% +$17.1K 0.14% 99
2022
Q2 		$436K Sell
2,845
-620
-18% -$94.7K 0.14% 103
2022
Q1 		$562K Buy
+3,465
New +$503K 0.16% 97
2021
Q3 		– Sell
-1,877
Closed -$211K – 102
2021
Q2 		$211K Sell
1,877
-89
-5% -$10K 0.1% 93
2021
Q1 		$213K Buy
+1,966
New +$210K 0.1% 89

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Bryn Mawr Capital Management's ABBV Position: Q2 2026 in Review

Bryn Mawr Capital Management increased its AbbVie (ABBV) stake by 3.8% in Q2 2026, buying an estimated $70.1K and bringing the position to 8,879 shares worth $2.23M. The position accounts for 0.1% of the portfolio, ranked #150.

Bryn Mawr Capital Management first reported a position in ABBV in Q1 2021 and has held it in 20 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Bryn Mawr Capital Management held 8,879 shares of AbbVie worth $2.23M as of Q2 2026.
  • Bryn Mawr Capital Management bought 326 AbbVie shares in Q2 2026, an estimated $70.1K.
  • AbbVie made up 0.1% of Bryn Mawr Capital Management's portfolio in Q2 2026, its #150 holding.
  • Bryn Mawr Capital Management first reported a position in AbbVie in Q1 2021 and has held it in 20 quarters since.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Bryn Mawr Capital Management's 13F filing for Q2 2026, filed 3 Aug 2026.